The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Imbruvica® (Ibrutinib) given FDA accelerated approval in the treatment of R/R MZL
This week the Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for use in Marginal Zone Lymphoma (MZL) patients. Imbruvica® is a Bruton’s Tyrosine Kinase (BTK) targeting therapy that already has approval in other lymphoma subtypes such as CLL and WM. The newly approved indication for Imbruvica® is in R/R MZL patients who require systemic therapy having already received at least one anti-CD20-based therapy, and marks the first approved treatment in relapsed/refractory MZL. The accelerated approval in MZL means the approval is conditional upon continued study results and further trial data.
The accelerated approval comes after the results of the PCYC-1121 trial (NCT01980628), which were reported by Ariela Noy during the American Society of Hematology Annual Meeting 2016, where the Lymphoma Hub interviewed Stefano Luminari on the oral presentation. The PCYC-1121 study of Imbruvica® treatment in 63 MZL patients reported an overall response rate of 46% (95% CI: 33.4–59.1), with 42.9% achieving partial recovery and 3.2% achieving complete recovery.
References